|
US 11,858,978 B2 |
|
| Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| Heiko Schuster, Tuebingen (DE); Janet Peper, Freising (DE); Kevin Roehle, Tuebingen (DE); Philipp Wagner, Stuttgart (DE); and Hans-Georg Rammensee, Tuebingen (DE) |
| Assigned to IMMATICS BIOTECHNOLOGIES GMBH, Tuebingen (DE) |
| Filed by Immatics Biotechnologies GmbH, Tuebingen (DE) |
| Filed on Jun. 17, 2021, as Appl. No. 17/350,879. |
| Application 17/350,879 is a continuation of application No. 17/117,191, filed on Dec. 10, 2020, abandoned. |
| Application 17/117,191 is a continuation of application No. 16/911,109, filed on Jun. 24, 2020, granted, now 10,899,820, issued on Jan. 26, 2021. |
| Application 16/911,109 is a continuation of application No. 15/881,078, filed on Jan. 26, 2018, granted, now 10,738,100, issued on Aug. 11, 2020. |
| Claims priority of provisional application 62/451,255, filed on Jan. 27, 2017. |
| Claims priority of application No. 10 2017 101 671.6 (DE), filed on Jan. 27, 2017. |
| Prior Publication US 2022/0356227 A1, Nov. 10, 2022 |
| This patent is subject to a terminal disclaimer. |
| Int. Cl. A61K 39/00 (2006.01); C07K 14/74 (2006.01); A61P 35/00 (2006.01); G16B 30/00 (2019.01); C07K 14/47 (2006.01); C07K 16/28 (2006.01); C12Q 1/6886 (2018.01) |